Olaparib for Metastatic Castration-Resistant Prostate Cancer
2020 · New England Journal of Medicine · 2,172 citations
https://doi.org/10.1056/nejmoa1911440
S
Shahneen Sandhu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
642
Papers
35.1K
Citations
81
h-index
262
i10-index
Shahneen Sandhu is an academic researcher from Royal Women's Hospital. The author has contributed to research in topics: Prostate Cancer Treatment and Research & Cancer Immunotherapy and Biomarkers & Radiopharmaceutical Chemistry and Applications. The author has an h-index of 81, co-authored 546 publications.
ORCID: 0000-0002-8660-4475Papers by this author
works[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
2021 · The Lancet · 1,002 citations
https://doi.org/10.1016/s0140-6736(21)00237-3
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
2021 · The Lancet · 1,002 citations
https://doi.org/10.1016/s0140-6736(21)00237-3
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
2019 · The Lancet Oncology · 636 citations
https://doi.org/10.1016/s1470-2045(19)30684-9
Prostate cancer
2021 · The Lancet · 535 citations
https://doi.org/10.1016/s0140-6736(21)00950-8
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
2018 · Journal of Nuclear Medicine · 454 citations
https://doi.org/10.2967/jnumed.118.219352
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat